Department of Rheumatology, Gennoki Clinic, 2680-1 Nishiharuchika, Ina, Nagano 399-4431, Japan.
Mod Rheumatol. 2011 Dec;21(6):696-700. doi: 10.1007/s10165-011-0469-9. Epub 2011 May 24.
The patient described here is a 49-year-old woman who had hepatitis C virus (HCV) infection and rheumatoid arthritis (RA). Her RA had been successfully managed with methotrexate for about 10 years. After a sustained virological response was achieved with interferon therapy, treatment with adalimumab was instituted. This resulted in a rapid and sustained remission that lasted for more than a year, without HCV reactivation. The results in this case suggest that a sequential strategy, with initial HCV clearance followed by the targeting of remission with biologics, may be a favorable option in patients with RA and concomitant HCV infection.
这里描述的患者是一位 49 岁女性，患有丙型肝炎病毒（HCV）感染和类风湿关节炎（RA）。她的 RA 已通过甲氨蝶呤治疗成功控制了约 10 年。在干扰素治疗实现持续病毒学应答后，开始使用阿达木单抗治疗。这导致快速和持续缓解，持续时间超过一年，且 HCV 未再激活。本病例结果表明，对于同时患有 RA 和 HCV 感染的患者，初始 HCV 清除后再用生物制剂靶向缓解的序贯策略可能是一种有利的选择。
